In a recent article published in the Agefi, the year 2023 saw a rise in mergers and acquisitions in the biotech sector, despite a slowdown in IPOs. While 2024 promises to be an optimistic year, investors are urged to be cautious about the haste of start-ups to go public.
2024 looks set to be a promising year for biotech, with renewed optimism fuelled by economic and political changes. However, experts advise investors to remain cautious, particularly in view of start-ups’ haste to launch IPOs too soon.
Stefan Catsicas and Thomas Heimann emphasize the importance of understanding the development phases of biotech companies, and of being discerning about the use of funds raised. They also advise focusing on M&A rather than IPOs.
Segments such as oncology, severe autoimmune diseases and genomics are identified as promising, with a particular interest in microbiome technologies and longevity.
